Current trials and novel therapeutic targets for alcoholic hepatitis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2% of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735
Trends in the management and burden of alcoholic liver disease
Mathurin, P., & Bataller, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.006 · Cited by 288
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
Acute liver failure: mechanisms of hepatocyte injury and regeneration
Rutherford, A., & Chung, R. (2008) · Seminars in Liver Disease · doi:10.1055/s-2008-1073116 · Cited by 131
Taı̈eb, J., Delarche, C., Paradis, V., Mathurin, P., Grenier, A., Crestani, B., Dehoux, M., Thabut, D., Gougerot-Pocidalo, M.-A., Poynard, T., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00276-8 · Cited by 73
Cited by
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
Wu, X., Fan, X., Miyata, T., Kim, A., Cajigas-Du Ross, C. K., Ray, S., Huang, E., Taiwo, M., Arya, R., Wu, J., et al. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-030435 · Cited by 289
Bataller, R., Arab, J. P., & Shah, V. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2207599 · Cited by 259
Self-citationCho, Y., Bukong, T. N., Tornai, D., Babuta, M., Vlachos, I. S., Kanata, E., Catalano, D., & Szabo, G. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.029 · Cited by 143
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis
Liu, M., Cao, S., He, L., Gao, J., Arab, J. P., Cui, H., Xuan, W., Gao, Y., Sehrawat, T. S., Hamdan, F. H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24843-w · Cited by 120
Self-citation
Metadata
- Authors
- Singal, A. K., & Shah, V. H.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 70
- Issue
- 2
- Pages
- 305-313
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2910660480
- Cited by
- 117
- References
- 7
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current trials and novel therapeutic targets for alcoholic hepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2018.10.026
- The paper
- Singal, A. K., & Shah, V. H. (2019). Current trials and novel therapeutic targets for alcoholic hepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2018.10.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.